secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0000950170-23-007861
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences reports FY2022 net loss $68.2M; cash $276.6M; PALIZADE trial to start H1 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities totaled $276.6M as of Dec 31, 2022, up from $208.4M in 2021.
- Net loss for FY2022 was $68.2M ($1.01 per share) vs $54.6M ($1.04 per share) in 2021.
- R&D expenses for FY2022 increased to $51.0M from $38.9M, driven by advancing zetomipzomib and KZR-261 programs.
- PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis to initiate in H1 2023; PORTOLA Phase 2a in autoimmune hepatitis ongoing.
- KZR-261 dose escalation currently enrolling Cohort 6; dose expansion study planned for H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023007861/0000950170-23-007861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023007861/kzr-20230314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer